Head Of Research
and access,
Karl has worked in the Life Sciences sector for over 25 years and has covered a number of impressive stocks and transactions during his career, including the $1 billion IPO of Serono on the New York Stock Exchange as well as the IPO of Genmab (which was the largest IPO in Europe at the time). In addition to this, Karl has a PhD in combined scientific training with finance (MSc) and has been a top rated analyst in the UK, US and Canada.
